메뉴 건너뛰기




Volumn 21, Issue 2, 2008, Pages 239-250

Modulating graft-versus-host disease to enhance the graft-versus-leukemia effect

Author keywords

donor lymphocyte infusion (DLI); graft versus host disease; graft versus leukemia (GVL)

Indexed keywords

ALEMTUZUMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYTARABINE; FLUDARABINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 5; INTERLEUKIN 7; METHOTREXATE; RAPAMYCIN; RECOMBINANT INTERLEUKIN 2; TACROLIMUS; TUMOR NECROSIS FACTOR;

EID: 44049106070     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2008.02.012     Document Type: Review
Times cited : (11)

References (89)
  • 1
    • 84960948722 scopus 로고
    • Treatment of murine leukaemia with X rays and homologous bone marrow. Preliminary communication
    • Barnes D.W.H., Corp M.J., Loutit J.F., et al. Treatment of murine leukaemia with X rays and homologous bone marrow. Preliminary communication. British Medical Journal 2 (1956) 626-627
    • (1956) British Medical Journal , vol.2 , pp. 626-627
    • Barnes, D.W.H.1    Corp, M.J.2    Loutit, J.F.3
  • 2
    • 44049099424 scopus 로고
    • Immunological and histological response following spleen treatment in irradiated mice
    • Mitchel J.S., Holmes B.E., and Smith C.L. (Eds), Oliver and Boyd, Edinburgh
    • Barnes D.W.H., and Loutit J.F. Immunological and histological response following spleen treatment in irradiated mice. In: Mitchel J.S., Holmes B.E., and Smith C.L. (Eds). Progress in radiobiology (1956), Oliver and Boyd, Edinburgh 291
    • (1956) Progress in radiobiology , pp. 291
    • Barnes, D.W.H.1    Loutit, J.F.2
  • 5
    • 0025100777 scopus 로고
    • Graft-versus-leukemia reactions after bone marrow transplantation
    • Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75 (1990) 555-562
    • (1990) Blood , vol.75 , pp. 555-562
    • Horowitz, M.M.1    Gale, R.P.2    Sondel, P.M.3
  • 6
    • 0023690307 scopus 로고
    • Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion
    • Goldman J.M., Gale R.P., Horowitz M.M., et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Annals of Internal Medicine 108 (1988) 806-814
    • (1988) Annals of Internal Medicine , vol.108 , pp. 806-814
    • Goldman, J.M.1    Gale, R.P.2    Horowitz, M.M.3
  • 7
    • 0023940821 scopus 로고
    • Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase, Importance of a graft-versus-leukaemia effect
    • Apperley J.F., Mauro F.R., Goldman J.M., et al. Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase, Importance of a graft-versus-leukaemia effect. British Journal of Haematology 69 (1988) 239-245
    • (1988) British Journal of Haematology , vol.69 , pp. 239-245
    • Apperley, J.F.1    Mauro, F.R.2    Goldman, J.M.3
  • 8
    • 0026049124 scopus 로고
    • T-cell depletion of HLA-identical transplants in leukemia
    • Marmont A., Horowitz M.M., Gale R.P., et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 78 (1991) 2120-2130
    • (1991) Blood , vol.78 , pp. 2120-2130
    • Marmont, A.1    Horowitz, M.M.2    Gale, R.P.3
  • 9
    • 0018764352 scopus 로고
    • Antileukemic effect of graft-versus-host disease in recipients of allogeneic-marrow grafts
    • Weiden P.L., Flournoy N., Thomas E.D., et al. Antileukemic effect of graft-versus-host disease in recipients of allogeneic-marrow grafts. The New England Journal of Medicine 300 (1979) 1068-1073
    • (1979) The New England Journal of Medicine , vol.300 , pp. 1068-1073
    • Weiden, P.L.1    Flournoy, N.2    Thomas, E.D.3
  • 10
    • 0019861205 scopus 로고
    • Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation
    • Weiden P.L., Sullivan K., Flournoy N., et al. Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. The New England Journal of Medicine 304 (1981) 1529-1533
    • (1981) The New England Journal of Medicine , vol.304 , pp. 1529-1533
    • Weiden, P.L.1    Sullivan, K.2    Flournoy, N.3
  • 11
    • 44049104351 scopus 로고
    • Evidence for a graft versus leukemia effect in clinical bone marrow transplantation
    • Horowitz M.M. Evidence for a graft versus leukemia effect in clinical bone marrow transplantation. Experimental Hematology 16 (1988) 547
    • (1988) Experimental Hematology , vol.16 , pp. 547
    • Horowitz, M.M.1
  • 12
    • 0018126513 scopus 로고
    • Remission of relapsed leukaemia during a graft-versus-host reaction. A 'graft-versus-leukaemia reaction' in man?
    • Odom L.F., August C.S., Githens J.H., et al. Remission of relapsed leukaemia during a graft-versus-host reaction. A 'graft-versus-leukaemia reaction' in man?. The Lancet 2 (1978) 537-540
    • (1978) The Lancet , vol.2 , pp. 537-540
    • Odom, L.F.1    August, C.S.2    Githens, J.H.3
  • 13
    • 0025329042 scopus 로고
    • Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect
    • Higano C.S., Brixey M., Bryant E.M., et al. Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect. Transfusion 50 (1990) 175-177
    • (1990) Transfusion , vol.50 , pp. 175-177
    • Higano, C.S.1    Brixey, M.2    Bryant, E.M.3
  • 14
    • 0026731551 scopus 로고
    • Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation. Apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression
    • Collins R.H., Rogers Z.R., Bennett M., et al. Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation. Apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Transplantation 10 (1992) 391-395
    • (1992) Bone Marrow Transplantation , vol.10 , pp. 391-395
    • Collins, R.H.1    Rogers, Z.R.2    Bennett, M.3
  • 15
    • 0030642156 scopus 로고    scopus 로고
    • Graft-versus-leukemia effect of allogeneic bone marrow transplantation and donor mononuclear cell infusions
    • Winter J. (Ed), Kluwer Academic Publishers, Boston
    • Porter D., and Antin J. Graft-versus-leukemia effect of allogeneic bone marrow transplantation and donor mononuclear cell infusions. In: Winter J. (Ed). Blood Stem Cell Transplantation vol. 77 (1997), Kluwer Academic Publishers, Boston 57-85
    • (1997) Blood Stem Cell Transplantation , vol.77 , pp. 57-85
    • Porter, D.1    Antin, J.2
  • 16
    • 0029100438 scopus 로고
    • Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients
    • Kolb H.J., Schattenberg A., Goldman J.M., et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86 (1995) 2041-2050
    • (1995) Blood , vol.86 , pp. 2041-2050
    • Kolb, H.J.1    Schattenberg, A.2    Goldman, J.M.3
  • 17
    • 2942712161 scopus 로고    scopus 로고
    • Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation
    • [see comments]
    • Collins Jr. R.H., Shpilberg O., Drobyski W.R., et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. [see comments]. Journal of Clinical Oncology 15 (1997) 433-444
    • (1997) Journal of Clinical Oncology , vol.15 , pp. 433-444
    • Collins Jr., R.H.1    Shpilberg, O.2    Drobyski, W.R.3
  • 18
    • 0022647626 scopus 로고
    • Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation
    • Sullivan K.M., Deeg H.J., Sanders J., et al. Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation. Blood 67 (1986) 1172-1175
    • (1986) Blood , vol.67 , pp. 1172-1175
    • Sullivan, K.M.1    Deeg, H.J.2    Sanders, J.3
  • 19
    • 0024504726 scopus 로고
    • Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms
    • Sullivan K.M., Storb R., Buckner C.D., et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. The New England Journal of Medicine 320 (1989) 828-834
    • (1989) The New England Journal of Medicine , vol.320 , pp. 828-834
    • Sullivan, K.M.1    Storb, R.2    Buckner, C.D.3
  • 20
    • 34250191090 scopus 로고    scopus 로고
    • Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy
    • Koh L.P., Chen C.S., Tai B.C., et al. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy. Biology of Blood and Marrow Transplantation 13 (2007) 790-805
    • (2007) Biology of Blood and Marrow Transplantation , vol.13 , pp. 790-805
    • Koh, L.P.1    Chen, C.S.2    Tai, B.C.3
  • 21
    • 0024566585 scopus 로고
    • Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia
    • Sullivan K.M., Weiden P.L., Storb R., et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 73 (1989) 1720-1728
    • (1989) Blood , vol.73 , pp. 1720-1728
    • Sullivan, K.M.1    Weiden, P.L.2    Storb, R.3
  • 22
    • 0019538222 scopus 로고
    • Anti-leukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation
    • Weiden P.L., Flournoy N., Sanders J.E., et al. Anti-leukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation. Transplantation proceedings 13 (1981) 248-251
    • (1981) Transplantation proceedings , vol.13 , pp. 248-251
    • Weiden, P.L.1    Flournoy, N.2    Sanders, J.E.3
  • 23
    • 1342266375 scopus 로고    scopus 로고
    • Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia
    • Nordlander A., Mattsson J., Ringden O., et al. Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia. Biology of Blood and Marrow Transplantation 10 (2004) 195-203
    • (2004) Biology of Blood and Marrow Transplantation , vol.10 , pp. 195-203
    • Nordlander, A.1    Mattsson, J.2    Ringden, O.3
  • 24
    • 0038494593 scopus 로고    scopus 로고
    • Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation
    • Mielcarek M., Martin P.J., Leisenring W., et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 102 (2003) 756-762
    • (2003) Blood , vol.102 , pp. 756-762
    • Mielcarek, M.1    Martin, P.J.2    Leisenring, W.3
  • 25
    • 0034665674 scopus 로고    scopus 로고
    • Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors
    • Nash R.A., Antin J.H., Karanes C., et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 96 (2000) 2062-2068
    • (2000) Blood , vol.96 , pp. 2062-2068
    • Nash, R.A.1    Antin, J.H.2    Karanes, C.3
  • 26
    • 0032188990 scopus 로고    scopus 로고
    • Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation
    • Ratanatharathorn V., Nash R.A., Przepiorka D., et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 92 (1998) 2303-2314
    • (1998) Blood , vol.92 , pp. 2303-2314
    • Ratanatharathorn, V.1    Nash, R.A.2    Przepiorka, D.3
  • 27
    • 33947578933 scopus 로고    scopus 로고
    • Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation
    • Cutler C., Li S., Ho V.T., et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 109 (2007) 3108-3114
    • (2007) Blood , vol.109 , pp. 3108-3114
    • Cutler, C.1    Li, S.2    Ho, V.T.3
  • 28
    • 3342895823 scopus 로고    scopus 로고
    • Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton
    • Sarbassov D.D., Ali S.M., Kim D.H., et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Current Biology 14 (2004) 1296-1302
    • (2004) Current Biology , vol.14 , pp. 1296-1302
    • Sarbassov, D.D.1    Ali, S.M.2    Kim, D.H.3
  • 29
    • 22144475453 scopus 로고    scopus 로고
    • Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells
    • Baan C.C., van der Mast B.J., Klepper M., et al. Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation 80 (2005) 110-117
    • (2005) Transplantation , vol.80 , pp. 110-117
    • Baan, C.C.1    van der Mast, B.J.2    Klepper, M.3
  • 30
    • 33745633856 scopus 로고    scopus 로고
    • Inhibition of CD4+ CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production
    • Zeiser R., Nguyen V.H., Beilhack A., et al. Inhibition of CD4+ CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 108 (2006) 390-399
    • (2006) Blood , vol.108 , pp. 390-399
    • Zeiser, R.1    Nguyen, V.H.2    Beilhack, A.3
  • 31
    • 20444373376 scopus 로고    scopus 로고
    • Rapamycin selectively expands CD4+ CD25+ FoxP3+ regulatory T cells
    • Battaglia M., Stabilini A., and Roncarolo M.G. Rapamycin selectively expands CD4+ CD25+ FoxP3+ regulatory T cells. Blood 105 (2005) 4743-4748
    • (2005) Blood , vol.105 , pp. 4743-4748
    • Battaglia, M.1    Stabilini, A.2    Roncarolo, M.G.3
  • 32
    • 0032105481 scopus 로고    scopus 로고
    • Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression
    • Sehgal S.N. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clinical Biochemistry 31 (1998) 335-340
    • (1998) Clinical Biochemistry , vol.31 , pp. 335-340
    • Sehgal, S.N.1
  • 33
    • 0041941520 scopus 로고    scopus 로고
    • Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation
    • Antin J.H., Kim H.T., Cutler C., et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 102 (2003) 1601-1605
    • (2003) Blood , vol.102 , pp. 1601-1605
    • Antin, J.H.1    Kim, H.T.2    Cutler, C.3
  • 34
    • 11144354152 scopus 로고    scopus 로고
    • Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation
    • Cutler C., Kim H.T., Hochberg E., et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biology of Blood and Marrow Transplantation 10 (2004) 328-336
    • (2004) Biology of Blood and Marrow Transplantation , vol.10 , pp. 328-336
    • Cutler, C.1    Kim, H.T.2    Hochberg, E.3
  • 35
    • 0344925935 scopus 로고    scopus 로고
    • Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT)
    • Champlin R.E., Schmitz N., Horowitz M.M., et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 95 (2000) 3702-3709
    • (2000) Blood , vol.95 , pp. 3702-3709
    • Champlin, R.E.1    Schmitz, N.2    Horowitz, M.M.3
  • 36
    • 0035099986 scopus 로고    scopus 로고
    • Peripheral blood stem cells for allogeneic transplantation: a review
    • Cutler C., and Antin J.H. Peripheral blood stem cells for allogeneic transplantation: a review. Stem Cells 19 (2001) 108-117
    • (2001) Stem Cells , vol.19 , pp. 108-117
    • Cutler, C.1    Antin, J.H.2
  • 37
    • 0035905908 scopus 로고    scopus 로고
    • Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers
    • Bensinger W.I., Martin P.J., Storer B., et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. The New England Journal of Medicine 344 (2001) 175-181
    • (2001) The New England Journal of Medicine , vol.344 , pp. 175-181
    • Bensinger, W.I.1    Martin, P.J.2    Storer, B.3
  • 38
    • 33845478320 scopus 로고    scopus 로고
    • Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation
    • Schmitz N., Eapen M., Horowitz M.M., et al. Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood 108 (2006) 4288-4290
    • (2006) Blood , vol.108 , pp. 4288-4290
    • Schmitz, N.1    Eapen, M.2    Horowitz, M.M.3
  • 39
    • 36048969811 scopus 로고    scopus 로고
    • Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival
    • Eapen M., Logan B.R., Confer D.L., et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biology of Blood and Marrow Transplantation 13 (2007) 1461-1468
    • (2007) Biology of Blood and Marrow Transplantation , vol.13 , pp. 1461-1468
    • Eapen, M.1    Logan, B.R.2    Confer, D.L.3
  • 40
    • 39149133203 scopus 로고    scopus 로고
    • Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival
    • Valcarcel D., Martino R., Caballero D., et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. Journal of Clinical Oncology 26 (2008) 577-584
    • (2008) Journal of Clinical Oncology , vol.26 , pp. 577-584
    • Valcarcel, D.1    Martino, R.2    Caballero, D.3
  • 41
    • 0033971243 scopus 로고    scopus 로고
    • Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle
    • Blaise D., Kuentz M., Fortanier C., et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle. Journal of Clinical Oncology 18 (2000) 537-546
    • (2000) Journal of Clinical Oncology , vol.18 , pp. 537-546
    • Blaise, D.1    Kuentz, M.2    Fortanier, C.3
  • 42
    • 0032406754 scopus 로고    scopus 로고
    • A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies
    • Vigorito A.C., Azevedo W.M., Marques J.F., et al. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplantation 22 (1998) 1145-1151
    • (1998) Bone Marrow Transplantation , vol.22 , pp. 1145-1151
    • Vigorito, A.C.1    Azevedo, W.M.2    Marques, J.F.3
  • 43
    • 0032423127 scopus 로고    scopus 로고
    • Chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case-control study. Spanish Group of Allo-PBT
    • Solano C., Martinez C., Brunet S., et al. Chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case-control study. Spanish Group of Allo-PBT. Bone Marrow Transplantation 22 (1998) 1129-1135
    • (1998) Bone Marrow Transplantation , vol.22 , pp. 1129-1135
    • Solano, C.1    Martinez, C.2    Brunet, S.3
  • 44
    • 0037100280 scopus 로고    scopus 로고
    • Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial
    • Flowers M.E.D., Parker P.M., Johnston L.J., et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 100 (2002) 415-419
    • (2002) Blood , vol.100 , pp. 415-419
    • Flowers, M.E.D.1    Parker, P.M.2    Johnston, L.J.3
  • 45
    • 0019448114 scopus 로고
    • Interleukin-2 augments natural killer cell activity
    • Henney C.S., Kuribayashi K., Kern D.E., et al. Interleukin-2 augments natural killer cell activity. Nature 291 (1981) 335-338
    • (1981) Nature , vol.291 , pp. 335-338
    • Henney, C.S.1    Kuribayashi, K.2    Kern, D.E.3
  • 47
    • 0023834370 scopus 로고
    • In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity
    • Fierro M.T., Liao X.S., Lusso P., et al. In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity. Leukemia 2 (1988) 50-54
    • (1988) Leukemia , vol.2 , pp. 50-54
    • Fierro, M.T.1    Liao, X.S.2    Lusso, P.3
  • 48
    • 0023907713 scopus 로고
    • Cytotoxicity of interleukin-2-activated lymphocytes for autologous normal blood mononuclear cells
    • Oshimi K., Oshimi Y., Saito H., et al. Cytotoxicity of interleukin-2-activated lymphocytes for autologous normal blood mononuclear cells. Journal of Immunological Methods 109 (1988) 161-168
    • (1988) Journal of Immunological Methods , vol.109 , pp. 161-168
    • Oshimi, K.1    Oshimi, Y.2    Saito, H.3
  • 49
    • 0023581741 scopus 로고
    • Inhibition of clonogenic growth of fresh leukemia cells by unstimulated and IL-2 stimulated NK cells of normal donors
    • Lotzova E., Savary C.A., and Herberman R.B. Inhibition of clonogenic growth of fresh leukemia cells by unstimulated and IL-2 stimulated NK cells of normal donors. Leukemia Research 11 (1987) 1059-1066
    • (1987) Leukemia Research , vol.11 , pp. 1059-1066
    • Lotzova, E.1    Savary, C.A.2    Herberman, R.B.3
  • 50
    • 0026070124 scopus 로고
    • Defective lymphokine-activated killer cell generation and activity in acute leukemia patients with active disease
    • Foa R., Fierro M.T., Cesano A., et al. Defective lymphokine-activated killer cell generation and activity in acute leukemia patients with active disease. Blood 78 (1991) 1041-1046
    • (1991) Blood , vol.78 , pp. 1041-1046
    • Foa, R.1    Fierro, M.T.2    Cesano, A.3
  • 51
    • 0025908320 scopus 로고
    • Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: a pilot study
    • Foa R., Meloni G., Tosti S., et al. Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: a pilot study. British Journal of Haematology 77 (1991) 491-496
    • (1991) British Journal of Haematology , vol.77 , pp. 491-496
    • Foa, R.1    Meloni, G.2    Tosti, S.3
  • 52
    • 0025108711 scopus 로고
    • IL-2 activated cell-mediated immunotherapy: control of minimal residual disease in malignant disorders by allogeneic lymphocytes and IL-2
    • Slavin S., Ackerstein A., Kedar E., et al. IL-2 activated cell-mediated immunotherapy: control of minimal residual disease in malignant disorders by allogeneic lymphocytes and IL-2. Bone Marrow Transplantation 1 6 Suppl (1990) 86-90
    • (1990) Bone Marrow Transplantation , vol.1 , Issue.6 SUPPL , pp. 86-90
    • Slavin, S.1    Ackerstein, A.2    Kedar, E.3
  • 53
    • 0026499915 scopus 로고
    • Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders: I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL-2-activated cell-mediated immunotherapy
    • Weiss L., Reich S., and Slavin S. Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders: I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL-2-activated cell-mediated immunotherapy. Cancer Investigation 10 (1992) 19-26
    • (1992) Cancer Investigation , vol.10 , pp. 19-26
    • Weiss, L.1    Reich, S.2    Slavin, S.3
  • 54
    • 0026554039 scopus 로고
    • Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia - a phase II study
    • Lim S.H., Newland A.C., Kelsey S., et al. Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia - a phase II study. Cancer Immunology Immunotherapy 34 (1992) 337-342
    • (1992) Cancer Immunology Immunotherapy , vol.34 , pp. 337-342
    • Lim, S.H.1    Newland, A.C.2    Kelsey, S.3
  • 55
    • 0028145247 scopus 로고
    • Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia
    • Meloni G., Foa R., Vignetti M., et al. Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood 84 (1994) 2158-2163
    • (1994) Blood , vol.84 , pp. 2158-2163
    • Meloni, G.1    Foa, R.2    Vignetti, M.3
  • 56
    • 0025615912 scopus 로고
    • Recombinant interleukin 2 for acute myeloid leukaemia in first complete remission: a pilot study
    • Macdonald D., Jiang Y.Z., Gordon A.A., et al. Recombinant interleukin 2 for acute myeloid leukaemia in first complete remission: a pilot study. Leukemia Research 14 (1990) 967-973
    • (1990) Leukemia Research , vol.14 , pp. 967-973
    • Macdonald, D.1    Jiang, Y.Z.2    Gordon, A.A.3
  • 57
    • 0026512503 scopus 로고
    • Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation
    • Soiffer R.J., Murray C., Cochran K., et al. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood 79 (1992) 517-526
    • (1992) Blood , vol.79 , pp. 517-526
    • Soiffer, R.J.1    Murray, C.2    Cochran, K.3
  • 58
    • 6444245790 scopus 로고    scopus 로고
    • The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission
    • Blaise D., Attal M., Pico J.L., et al. The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission. Leukemia & Lymphoma 25 (1997) 469-478
    • (1997) Leukemia & Lymphoma , vol.25 , pp. 469-478
    • Blaise, D.1    Attal, M.2    Pico, J.L.3
  • 59
    • 0026492347 scopus 로고
    • Immunotherapy of minimal residual disease in conjunction with autologous and allogeneic bone marrow transplantation (BMT)
    • Slavin S., Or R., Kapelushnik Y., et al. Immunotherapy of minimal residual disease in conjunction with autologous and allogeneic bone marrow transplantation (BMT). Leukemia 4 6 Suppl (1992) 164-166
    • (1992) Leukemia , vol.4 , Issue.6 SUPPL , pp. 164-166
    • Slavin, S.1    Or, R.2    Kapelushnik, Y.3
  • 60
    • 0028332772 scopus 로고
    • Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation
    • Soiffer R.J., Murray C., Gonin R., et al. Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood 84 (1994) 964-971
    • (1994) Blood , vol.84 , pp. 964-971
    • Soiffer, R.J.1    Murray, C.2    Gonin, R.3
  • 61
    • 27144500976 scopus 로고    scopus 로고
    • Reduced frequency of FOXP3+ CD4+ CD25+ regulatory T cells in patients with chronic graft-versus-host disease
    • Zorn E., Kim H.T., Lee S.J., et al. Reduced frequency of FOXP3+ CD4+ CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood 106 (2005) 2903-2911
    • (2005) Blood , vol.106 , pp. 2903-2911
    • Zorn, E.1    Kim, H.T.2    Lee, S.J.3
  • 62
    • 33747801470 scopus 로고    scopus 로고
    • IL-2 regulates FOXP3 expression in human CD4+ CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo
    • Zorn E., Nelson E.A., Mohseni M., et al. IL-2 regulates FOXP3 expression in human CD4+ CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 108 (2006) 1571-1579
    • (2006) Blood , vol.108 , pp. 1571-1579
    • Zorn, E.1    Nelson, E.A.2    Mohseni, M.3
  • 63
    • 0035496939 scopus 로고    scopus 로고
    • Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease
    • Alpdogan O., Schmaltz C., Muriglan S.J., et al. Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease. Blood 98 (2001) 2256-2265
    • (2001) Blood , vol.98 , pp. 2256-2265
    • Alpdogan, O.1    Schmaltz, C.2    Muriglan, S.J.3
  • 64
    • 0032701975 scopus 로고    scopus 로고
    • IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation
    • Teshima T., Hill G.R., Pan L., et al. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. The Journal of Clinical Investigation 104 (1999) 317-325
    • (1999) The Journal of Clinical Investigation , vol.104 , pp. 317-325
    • Teshima, T.1    Hill, G.R.2    Pan, L.3
  • 65
    • 0032055912 scopus 로고    scopus 로고
    • Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic progenitors
    • Bomberger C., Singh-Jairam M., Rodey G., et al. Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic progenitors. Blood 91 (1998) 2588-2600
    • (1998) Blood , vol.91 , pp. 2588-2600
    • Bomberger, C.1    Singh-Jairam, M.2    Rodey, G.3
  • 66
    • 0030709464 scopus 로고    scopus 로고
    • Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice
    • Yang Y.G., Sergio J.J., Pearson D.A., et al. Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice. Blood 90 (1997) 4651-4660
    • (1997) Blood , vol.90 , pp. 4651-4660
    • Yang, Y.G.1    Sergio, J.J.2    Pearson, D.A.3
  • 67
    • 0036838671 scopus 로고    scopus 로고
    • Interleukin 18 preserves a perforin-dependent graft-versus-leukemia effect after allogeneic bone marrow transplantation
    • Reddy P., Teshima T., Hildebrandt G., et al. Interleukin 18 preserves a perforin-dependent graft-versus-leukemia effect after allogeneic bone marrow transplantation. Blood 100 (2002) 3429-3431
    • (2002) Blood , vol.100 , pp. 3429-3431
    • Reddy, P.1    Teshima, T.2    Hildebrandt, G.3
  • 68
    • 0029868846 scopus 로고    scopus 로고
    • Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation
    • Slavin S., Naparstek E., Nagler A., et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 87 (1996) 2195-2204
    • (1996) Blood , vol.87 , pp. 2195-2204
    • Slavin, S.1    Naparstek, E.2    Nagler, A.3
  • 69
    • 23444449333 scopus 로고
    • Induction of graft-vs-host disease as immunotherapy for relapsed chronic myelogenous leukemia
    • Porter D.L., Roth M.S., McGarigle C., et al. Induction of graft-vs-host disease as immunotherapy for relapsed chronic myelogenous leukemia. The New England Journal of Medicine 330 (1994) 100-106
    • (1994) The New England Journal of Medicine , vol.330 , pp. 100-106
    • Porter, D.L.1    Roth, M.S.2    McGarigle, C.3
  • 70
    • 0038364158 scopus 로고    scopus 로고
    • Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions
    • Raiola A.M., Van Lint M.T., Valbonesi M., et al. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions. Bone Marrow Transplantation 31 (2003) 687-693
    • (2003) Bone Marrow Transplantation , vol.31 , pp. 687-693
    • Raiola, A.M.1    Van Lint, M.T.2    Valbonesi, M.3
  • 71
    • 0037100284 scopus 로고    scopus 로고
    • Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose
    • Guglielmi C., Arcese W., Dazzi F., et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 100 (2002) 397-405
    • (2002) Blood , vol.100 , pp. 397-405
    • Guglielmi, C.1    Arcese, W.2    Dazzi, F.3
  • 72
    • 0029092530 scopus 로고
    • Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease
    • Mackinnon S., Papadapoulos E.B., Carabasi M.H., et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86 (1995) 1261-1268
    • (1995) Blood , vol.86 , pp. 1261-1268
    • Mackinnon, S.1    Papadapoulos, E.B.2    Carabasi, M.H.3
  • 73
    • 0033962014 scopus 로고    scopus 로고
    • Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia
    • Dazzi F., Szydlo R.M., Craddock C., et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 95 (2000) 67-71
    • (2000) Blood , vol.95 , pp. 67-71
    • Dazzi, F.1    Szydlo, R.M.2    Craddock, C.3
  • 74
    • 20244374668 scopus 로고    scopus 로고
    • Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant
    • Alyea E.P., Soiffer R.J., Canning C., et al. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 91 (1998) 3671-3680
    • (1998) Blood , vol.91 , pp. 3671-3680
    • Alyea, E.P.1    Soiffer, R.J.2    Canning, C.3
  • 75
    • 0030815867 scopus 로고    scopus 로고
    • Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation
    • Lokhorst H.M., Schattenberg A., Cornelissen J.J., et al. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 90 (1997) 4206-4211
    • (1997) Blood , vol.90 , pp. 4206-4211
    • Lokhorst, H.M.1    Schattenberg, A.2    Cornelissen, J.J.3
  • 76
    • 0033844816 scopus 로고    scopus 로고
    • Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome
    • Lokhorst H.M., Schattenberg A., Cornelissen J.J., et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. Journal of Clinical Oncology 18 (2000) 3031-3037
    • (2000) Journal of Clinical Oncology , vol.18 , pp. 3031-3037
    • Lokhorst, H.M.1    Schattenberg, A.2    Cornelissen, J.J.3
  • 77
    • 4243319817 scopus 로고    scopus 로고
    • CD6 T cell depleted allogeneic bone marrow transplant followed by CD4+ donor lymphocyte infusion for patients with multiple myeloma
    • Alyea E., Schossman R., Canning C., et al. CD6 T cell depleted allogeneic bone marrow transplant followed by CD4+ donor lymphocyte infusion for patients with multiple myeloma. Blood 94 (1999) 609a
    • (1999) Blood , vol.94
    • Alyea, E.1    Schossman, R.2    Canning, C.3
  • 78
    • 34948866783 scopus 로고    scopus 로고
    • Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning
    • Kahl C., Storer B.E., Sandmaier B.M., et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 110 (2007) 2744-2748
    • (2007) Blood , vol.110 , pp. 2744-2748
    • Kahl, C.1    Storer, B.E.2    Sandmaier, B.M.3
  • 79
    • 20144362213 scopus 로고    scopus 로고
    • Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning
    • Baron F., Maris M.B., Sandmaier B.M., et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Journal of Clinical Oncology 23 (2005) 1993-2003
    • (2005) Journal of Clinical Oncology , vol.23 , pp. 1993-2003
    • Baron, F.1    Maris, M.B.2    Sandmaier, B.M.3
  • 80
    • 0141475940 scopus 로고    scopus 로고
    • Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation
    • Dey B.R., McAfee S., Colby C., et al. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biology of Blood and Marrow Transplantation 9 (2003) 320-329
    • (2003) Biology of Blood and Marrow Transplantation , vol.9 , pp. 320-329
    • Dey, B.R.1    McAfee, S.2    Colby, C.3
  • 81
    • 0842307308 scopus 로고    scopus 로고
    • Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses
    • Peggs K.S., Thomson K., Hart D.P., et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood 103 (2004) 1548-1556
    • (2004) Blood , vol.103 , pp. 1548-1556
    • Peggs, K.S.1    Thomson, K.2    Hart, D.P.3
  • 82
    • 9144234680 scopus 로고    scopus 로고
    • Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning
    • Bethge W.A., Hegenbart U., Stuart M.J., et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood 103 (2004) 790-795
    • (2004) Blood , vol.103 , pp. 790-795
    • Bethge, W.A.1    Hegenbart, U.2    Stuart, M.J.3
  • 83
    • 34548544801 scopus 로고    scopus 로고
    • Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes
    • Peggs K.S., Sureda A., Qian W., et al. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. British Journal of Haematology 139 (2007) 70-80
    • (2007) British Journal of Haematology , vol.139 , pp. 70-80
    • Peggs, K.S.1    Sureda, A.2    Qian, W.3
  • 84
    • 37349000995 scopus 로고    scopus 로고
    • High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma
    • Bloor A.J., Thomson K., Chowdhry N., et al. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biology of Blood and Marrow Transplantation 14 (2008) 50-58
    • (2008) Biology of Blood and Marrow Transplantation , vol.14 , pp. 50-58
    • Bloor, A.J.1    Thomson, K.2    Chowdhry, N.3
  • 85
    • 24944495973 scopus 로고    scopus 로고
    • Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome
    • Schmid C., Schleuning M., Ledderose G., et al. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. Journal of Clinical Oncology 23 (2005) 5675-5687
    • (2005) Journal of Clinical Oncology , vol.23 , pp. 5675-5687
    • Schmid, C.1    Schleuning, M.2    Ledderose, G.3
  • 86
    • 0028871935 scopus 로고
    • CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation
    • Giralt S., Hester J., Huh Y., et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 86 (1995) 4337-4343
    • (1995) Blood , vol.86 , pp. 4337-4343
    • Giralt, S.1    Hester, J.2    Huh, Y.3
  • 87
    • 0030843493 scopus 로고    scopus 로고
    • HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia
    • Bonini C., Ferrari G., Verzeletti S., et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276 (1997) 1719-1724
    • (1997) Science , vol.276 , pp. 1719-1724
    • Bonini, C.1    Ferrari, G.2    Verzeletti, S.3
  • 88
    • 44049099161 scopus 로고
    • Transfer of the HSV-tK gene into donor peripheral blood lymphocytes for in vivo immunomodulation of donor antitumor immunity after allo- BMT
    • [Meeting abstract]
    • Verzeletti S., Bonini C., Traversari C., et al. Transfer of the HSV-tK gene into donor peripheral blood lymphocytes for in vivo immunomodulation of donor antitumor immunity after allo- BMT. [Meeting abstract]. Gene Therapy 1 (1994) S24
    • (1994) Gene Therapy , vol.1
    • Verzeletti, S.1    Bonini, C.2    Traversari, C.3
  • 89
    • 2642691791 scopus 로고
    • Retroviral vector gene transfer into donor peripheral blood lymphocytes for in vitro selection and in vivo immunomodulation of donor antitumor immunity after allo-BMT
    • [Meeting abstract]
    • Verzeletti S., Bonini C., Traversari C., et al. Retroviral vector gene transfer into donor peripheral blood lymphocytes for in vitro selection and in vivo immunomodulation of donor antitumor immunity after allo-BMT. [Meeting abstract]. Journal of Cellular Biochemistry 21A Suppl (1995) 356
    • (1995) Journal of Cellular Biochemistry , vol.21 A , Issue.SUPPL , pp. 356
    • Verzeletti, S.1    Bonini, C.2    Traversari, C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.